{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1038/s41467-026-73300-z","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471470","label":"url"}],"paper_title":{"en":"Protein-based pan-RAS inhibitor induces tumor regression in female mice via IFNγ and CD8+ T cell-dependent tumor necrosis","ja":"Protein-based pan-RAS inhibitor induces tumor regression in female mice via IFNγ and CD8+ T cell-dependent tumor necrosis"},"authors":{"en":[{"name":"Nomura, Teiko Komori"},{"name":"Heishima Kazuki"},{"name":"Mukai, Hidefumi"},{"name":"Arai, Kosuke"},{"name":"Elhelaly, Abdelazim Elsayed"},{"name":"Fuchigami, Hirobumi"},{"name":"Warashina, Shota"},{"name":"Tahara Tsuyoshi"},{"name":"Hyodo, Fuminori"},{"name":"Matsuo, Masayuki"},{"name":"Yasunaga, Masahiro"},{"name":"Aoki, Kazunori"},{"name":"Honda, Ryo"}],"ja":[{"name":"Nomura, Teiko Komori"},{"name":"平島 一輝"},{"name":"Mukai, Hidefumi"},{"name":"Arai, Kosuke"},{"name":"Elhelaly, Abdelazim Elsayed"},{"name":"Fuchigami, Hirobumi"},{"name":"Warashina, Shota"},{"name":"田原 強"},{"name":"Hyodo, Fuminori"},{"name":"Matsuo, Masayuki"},{"name":"Yasunaga, Masahiro"},{"name":"Aoki, Kazunori"},{"name":"Honda, Ryo"}]},"publication_date":"2026-05","publication_name":{"en":"Nature Communications","ja":"Nature Communications"},"volume":"17","number":"1","languages":["eng"],"referee":true,"identifiers":{"issn":["2041-1723"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.3389/FVETS.2026.1734339","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471473","label":"url"}],"paper_title":{"en":"Lysine lactylation regulates ATF4-mediated stress responses under glucose starvation in canine hemangiosarcoma","ja":"Lysine lactylation regulates ATF4-mediated stress responses under glucose starvation in canine hemangiosarcoma"},"authors":{"en":[{"name":"Suzuki, Tamami"},{"name":"Heishima Kazuki"},{"name":"Yamazaki, Jumpei"},{"name":"Yamazaki, Masaya"},{"name":"Kinoshita, Ryohei"},{"name":"Kim, Sangho"},{"name":"Hosoya, Kenji"},{"name":"Okamatsu-Ogura, Yuko"},{"name":"Sasaki, Michihito"},{"name":"Xu, Peng"},{"name":"Yan, Qin"},{"name":"Kimura, Takashi"},{"name":"Aoshima, Keisuke"}],"ja":[{"name":"Suzuki, Tamami"},{"name":"平島 一輝"},{"name":"Yamazaki, Jumpei"},{"name":"Yamazaki, Masaya"},{"name":"Kinoshita, Ryohei"},{"name":"Kim, Sangho"},{"name":"Hosoya, Kenji"},{"name":"Okamatsu-Ogura, Yuko"},{"name":"Sasaki, Michihito"},{"name":"Xu, Peng"},{"name":"Yan, Qin"},{"name":"Kimura, Takashi"},{"name":"Aoshima, Keisuke"}]},"publication_date":"2026-02","publication_name":{"en":"Frontiers in Veterinary Science","ja":"Frontiers in Veterinary Science"},"volume":"13","languages":["eng"],"referee":true,"identifiers":{"issn":["2297-1769"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1101/2025.08.12.669864","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471474","label":"url"}],"paper_title":{"en":"Lysine lactylation regulates ATF4-mediated stress responses under glucose starvation in canine hemangiosarcoma","ja":"Lysine lactylation regulates ATF4-mediated stress responses under glucose starvation in canine hemangiosarcoma"},"authors":{"en":[{"name":"Suzuki, Tamami"},{"name":"Heishima Kazuki"},{"name":"Yamazaki, Jumpei"},{"name":"Yamazaki, Masaya"},{"name":"Kinoshita, Ryohei"},{"name":"Kim, Sangho"},{"name":"Hosoya, Kenji"},{"name":"Okamatsu-Ogura, Yuko"},{"name":"Sasaki, Michihito"},{"name":"Xu, Peng"},{"name":"Yan, Qin"},{"name":"Kimura, Takashi"},{"name":"Aoshima, Keisuke"}],"ja":[{"name":"Suzuki, Tamami"},{"name":"平島 一輝"},{"name":"Yamazaki, Jumpei"},{"name":"Yamazaki, Masaya"},{"name":"Kinoshita, Ryohei"},{"name":"Kim, Sangho"},{"name":"Hosoya, Kenji"},{"name":"Okamatsu-Ogura, Yuko"},{"name":"Sasaki, Michihito"},{"name":"Xu, Peng"},{"name":"Yan, Qin"},{"name":"Kimura, Takashi"},{"name":"Aoshima, Keisuke"}]},"publication_date":"2025-08","languages":["eng"],"referee":true,"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471476","label":"url"}],"paper_title":{"en":"Restoration effect of chemically modified microRNA-143-3p on acute myocardial infarction in animal models","ja":"Restoration effect of chemically modified microRNA-143-3p on acute myocardial infarction in animal models"},"authors":{"en":[{"name":"Minatoguchi, S."},{"name":"Sugito, N."},{"name":"Heishima Kazuki"},{"name":"Ito, Y."},{"name":"Nakashima, R."},{"name":"Okura, H."},{"name":"Akao, Y."},{"name":"Minatoguchi, S."}],"ja":[{"name":"Minatoguchi, S."},{"name":"Sugito, N."},{"name":"平島 一輝"},{"name":"Ito, Y."},{"name":"Nakashima, R."},{"name":"Okura, H."},{"name":"Akao, Y."},{"name":"Minatoguchi, S."}]},"publication_date":"2025","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"15","number":"1","languages":["eng"],"referee":true,"identifiers":{"issn":["2045-2322"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471482","label":"url"}],"paper_title":{"en":"Restoration effect of chemically modified microRNA-143-3p on acute myocardial infarction in animal models","ja":"Restoration effect of chemically modified microRNA-143-3p on acute myocardial infarction in animal models"},"authors":{"en":[{"name":"Minatoguchi, S."},{"name":"Sugito, N."},{"name":"Heishima Kazuki"},{"name":"Ito, Y."},{"name":"Nakashima, R."},{"name":"Okura, H."},{"name":"Akao, Y."},{"name":"Minatoguchi, S."}],"ja":[{"name":"Minatoguchi, S."},{"name":"Sugito, N."},{"name":"平島 一輝"},{"name":"Ito, Y."},{"name":"Nakashima, R."},{"name":"Okura, H."},{"name":"Akao, Y."},{"name":"Minatoguchi, S."}]},"publication_date":"2024","publication_name":{"en":"Research Square","ja":"Research Square"},"languages":["eng"],"referee":true,"identifiers":{"issn":["2693-5015"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471480","label":"url"}],"paper_title":{"en":"Plasma microRNA-143 and microRNA-145 levels are elevated in patients with left ventricular dysfunction","ja":"Plasma microRNA-143 and microRNA-145 levels are elevated in patients with left ventricular dysfunction"},"authors":{"en":[{"name":"Murase, H."},{"name":"Minatoguchi, S."},{"name":"Heishima Kazuki"},{"name":"Yasuda, S."},{"name":"Satake, A."},{"name":"Yoshizumi, R."},{"name":"Komaki, H."},{"name":"Baba, S."},{"name":"Ojio, S."},{"name":"Tanaka, T."},{"name":"Akao, Y."},{"name":"Minatoguchi, S."},{"name":"Okura, H."}],"ja":[{"name":"Murase, H."},{"name":"Minatoguchi, S."},{"name":"平島 一輝"},{"name":"Yasuda, S."},{"name":"Satake, A."},{"name":"Yoshizumi, R."},{"name":"Komaki, H."},{"name":"Baba, S."},{"name":"Ojio, S."},{"name":"Tanaka, T."},{"name":"Akao, Y."},{"name":"Minatoguchi, S."},{"name":"Okura, H."}]},"publication_date":"2024","publication_name":{"en":"Heart and Vessels","ja":"Heart and Vessels"},"volume":"39","number":"10","starting_page":"867","ending_page":"876","languages":["eng"],"referee":true,"identifiers":{"issn":["0910-8327"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471478","label":"url"}],"paper_title":{"en":"Anti-tumor effects of chemically-modified microRNA143 Lipoplexes on colorectal cancer pelvic recurrence mouse model","ja":"Anti-tumor effects of chemically-modified microRNA143 Lipoplexes on colorectal cancer pelvic recurrence mouse model"},"authors":{"en":[{"name":"Heishima Kazuki"}],"ja":[{"name":"平島 一輝"}]},"publication_date":"2024","publication_name":{"en":"Cancer Science","ja":"Cancer Science"},"languages":["eng"],"referee":true,"identifiers":{"issn":["1347-9032"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38130992","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85180477815","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471487","label":"url"}],"paper_title":{"en":"Hemangiosarcoma in dogs as a potential non-rodent animal model for drug discovery research of angiosarcoma in humans","ja":"Hemangiosarcoma in dogs as a potential non-rodent animal model for drug discovery research of angiosarcoma in humans"},"authors":{"en":[{"name":"Heishima Kazuki"},{"name":"Aketa Naohiko"},{"name":"Heishima Mizuki"},{"name":"Kawachi Asuka"}],"ja":[{"name":"平島 一輝"},{"name":"Aketa Naohiko"},{"name":"Heishima Mizuki"},{"name":"Kawachi Asuka"}]},"description":{"en":"Since the domestication of dogs 10,000 years ago, they have shared their living environment with humans and have co-evolved. The breeding process that dogs have undergone in only a few centuries has led to a significant accumulation of specific genetic alterations that could induce particular diseases in certain breeds. These canine diseases are similar to what is found in humans with several differences; therefore, comparing such diseases occurring in humans and dogs can help discover novel disease mechanisms, pathways, and causal genetic factors. Human angiosarcoma (AS) and canine hemangiosarcoma (HSA), which are sarcomas originating from endothelium, are examples of diseases shared between humans and dogs. They exhibit similar characteristics and clinical behaviors, although with some critical differences resulting from evolution. In this review, we will describe the similarities and differences in terms of clinical and molecular characteristics between human AS and canine HSA, and discuss how these similarities and differences can be applied to advance the treatment of these diseases.","ja":"Since the domestication of dogs 10,000 years ago, they have shared their living environment with humans and have co-evolved. The breeding process that dogs have undergone in only a few centuries has led to a significant accumulation of specific genetic alterations that could induce particular diseases in certain breeds. These canine diseases are similar to what is found in humans with several differences; therefore, comparing such diseases occurring in humans and dogs can help discover novel disease mechanisms, pathways, and causal genetic factors. Human angiosarcoma (AS) and canine hemangiosarcoma (HSA), which are sarcomas originating from endothelium, are examples of diseases shared between humans and dogs. They exhibit similar characteristics and clinical behaviors, although with some critical differences resulting from evolution. In this review, we will describe the similarities and differences in terms of clinical and molecular characteristics between human AS and canine HSA, and discuss how these similarities and differences can be applied to advance the treatment of these diseases."},"publication_date":"2023-12-07","publication_name":{"en":"Frontiers in Oncology","ja":"Frontiers in Oncology"},"volume":"13","starting_page":"1250766","ending_page":"1250766","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3389/fonc.2023.1250766"],"issn":["2234-943X"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38213952","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85178177719","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471484","label":"url"}],"paper_title":{"en":"Antitumor effects of chemically modified miR-143 lipoplexes in a mouse model of pelvic colorectal cancer via myristoylated alanine-rich C kinase substrate downregulation","ja":"Antitumor effects of chemically modified miR-143 lipoplexes in a mouse model of pelvic colorectal cancer via myristoylated alanine-rich C kinase substrate downregulation"},"authors":{"en":[{"name":"Arima Jun"},{"name":"Taniguchi Kohei"},{"name":"Sugito Nobuhiko"},{"name":"Heishima Kazuki"},{"name":"Tokumaru Yoshihisa"},{"name":"Inomata Yosuke"},{"name":"Komura Kazumasa"},{"name":"Tanaka Tomohito"},{"name":"Shibata Masa-Aki"},{"name":"Lee Sang-Woong"},{"name":"Akao Yukihiro"}],"ja":[{"name":"Arima Jun"},{"name":"Taniguchi Kohei"},{"name":"Sugito Nobuhiko"},{"name":"平島 一輝"},{"name":"Tokumaru Yoshihisa"},{"name":"Inomata Yosuke"},{"name":"Komura Kazumasa"},{"name":"Tanaka Tomohito"},{"name":"Shibata Masa-Aki"},{"name":"Lee Sang-Woong"},{"name":"Akao Yukihiro"}]},"description":{"en":"Replenishing tumor-suppressor miRNAs (TS-miRNAs) is a potential next-generation nucleic acid-based therapeutic approach. Establishing an effective miRNA delivery system is essential to successful TS-miRNA therapy. To overcome vulnerability to RNA nucleases, we previously developed a chemically modified miRNA143-3p (CM-miR-143). In clinical practice, colorectal cancer (CRC) pelvic recurrence is an occasional challenge following curative resection, requiring a novel therapy because reoperative surgery poses a significant burden to the patient. Hence, we considered the use of CM-miR-143 as an alternative treatment. In this study, we used a mouse model bearing pelvic CRC adjacent to the rectum and investigated the anticancer effects of CM-miR-143 lipoplexes formulated from miRNA and a cationic liposome. Compared with commercial synthetic miR-143, CM-miR-143 lipoplexes accumulated heavily in regions of the pelvic CRC tumor where the blood flow was high. As a result, systemic administration of CM-miR-143 lipoplexes improved animal survival by significantly suppressing pelvic CRC tumors and relieving a lethal bowel obstruction caused by rectal compression. Detailed protein analysis revealed that the myristoylated alanine-rich C kinase is a novel target for CM-miR-143 lipoplexes. Our results suggest that CM-miR-143 is a potential next-generation drug candidate in the treatment of CRC pelvic recurrence.","ja":"Replenishing tumor-suppressor miRNAs (TS-miRNAs) is a potential next-generation nucleic acid-based therapeutic approach. Establishing an effective miRNA delivery system is essential to successful TS-miRNA therapy. To overcome vulnerability to RNA nucleases, we previously developed a chemically modified miRNA143-3p (CM-miR-143). In clinical practice, colorectal cancer (CRC) pelvic recurrence is an occasional challenge following curative resection, requiring a novel therapy because reoperative surgery poses a significant burden to the patient. Hence, we considered the use of CM-miR-143 as an alternative treatment. In this study, we used a mouse model bearing pelvic CRC adjacent to the rectum and investigated the anticancer effects of CM-miR-143 lipoplexes formulated from miRNA and a cationic liposome. Compared with commercial synthetic miR-143, CM-miR-143 lipoplexes accumulated heavily in regions of the pelvic CRC tumor where the blood flow was high. As a result, systemic administration of CM-miR-143 lipoplexes improved animal survival by significantly suppressing pelvic CRC tumors and relieving a lethal bowel obstruction caused by rectal compression. Detailed protein analysis revealed that the myristoylated alanine-rich C kinase is a novel target for CM-miR-143 lipoplexes. Our results suggest that CM-miR-143 is a potential next-generation drug candidate in the treatment of CRC pelvic recurrence."},"publication_date":"2023-11-15","publication_name":{"en":"Molecular Therapy. Nucleic Acids","ja":"Molecular Therapy. Nucleic Acids"},"volume":"34","starting_page":"102079","ending_page":"102079","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.omtn.2023.102079"],"issn":["2162-2531"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37300987","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85161329971","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471489","label":"url"}],"paper_title":{"en":"PARP deficiency causes hypersensitivity to Taxol through oxidative stress induced DNA damage","ja":"PARP deficiency causes hypersensitivity to Taxol through oxidative stress induced DNA damage"},"authors":{"en":[{"name":"Maeda Junko"},{"name":"Jepson Ben"},{"name":"Sadahiro Kohei"},{"name":"Murakami Mami"},{"name":"Sakai Hiroki"},{"name":"Heishima Kazuki"},{"name":"Akao Yukihiro"},{"name":"Kato A. Takamitsu"}],"ja":[{"name":"Maeda Junko"},{"name":"Jepson Ben"},{"name":"Sadahiro Kohei"},{"name":"Murakami Mami"},{"name":"Sakai Hiroki"},{"name":"平島 一輝"},{"name":"Akao Yukihiro"},{"name":"Kato A. Takamitsu"}]},"description":{"en":"Taxol is an antitumor drug derived from the bark of the Pacific Yew tree that inhibits microtubule disassembly, resulting in cell cycle arrest in late G2 and M phases. Additionally, Taxol increases cellular oxidative stress by generating reactive oxygen species. We hypothesized that the inhibition of specific DNA repair machinery/mechanisms would increase cellular sensitivity to the oxidative stress capacity of Taxol. Initial screening using Chinese hamster ovary (CHO) cell lines demonstrated that base excision repair deficiency, especially PARP deficiency, caused cellular Taxol hypersensitivity. Taxane diterpenes-containing Taxus yunnanensis extract also showed hypertoxicity in PARP deficient cells, which was consistent with other microtubule inhibitors like colcemid, vinblastine, and vincristine. Acute exposure of 50 nM Taxol treatment induced both significant cytotoxicity and M-phase arrest in PARP deficient cells, but caused neither significant cytotoxicity nor late G2-M cell cycle arrest in wild type cells. Acute exposure of 50 nM Taxol treatment induced oxidative stress and DNA damage. The antioxidant Ascorbic acid 2 glucoside partially reduced the cytotoxicity of Taxol in PARP deficient cell lines. Finally, the PARP inhibitor Olaparib increased cytotoxicity of Taxol in wild type CHO cells and two human cancer cell lines. Our study clearly demonstrates that cytotoxicity of Taxol would be enhanced by inhibiting PARP function as an enzyme implicated in DNA repair for oxidative stress.","ja":"Taxol is an antitumor drug derived from the bark of the Pacific Yew tree that inhibits microtubule disassembly, resulting in cell cycle arrest in late G2 and M phases. Additionally, Taxol increases cellular oxidative stress by generating reactive oxygen species. We hypothesized that the inhibition of specific DNA repair machinery/mechanisms would increase cellular sensitivity to the oxidative stress capacity of Taxol. Initial screening using Chinese hamster ovary (CHO) cell lines demonstrated that base excision repair deficiency, especially PARP deficiency, caused cellular Taxol hypersensitivity. Taxane diterpenes-containing Taxus yunnanensis extract also showed hypertoxicity in PARP deficient cells, which was consistent with other microtubule inhibitors like colcemid, vinblastine, and vincristine. Acute exposure of 50 nM Taxol treatment induced both significant cytotoxicity and M-phase arrest in PARP deficient cells, but caused neither significant cytotoxicity nor late G2-M cell cycle arrest in wild type cells. Acute exposure of 50 nM Taxol treatment induced oxidative stress and DNA damage. The antioxidant Ascorbic acid 2 glucoside partially reduced the cytotoxicity of Taxol in PARP deficient cell lines. Finally, the PARP inhibitor Olaparib increased cytotoxicity of Taxol in wild type CHO cells and two human cancer cell lines. Our study clearly demonstrates that cytotoxicity of Taxol would be enhanced by inhibiting PARP function as an enzyme implicated in DNA repair for oxidative stress."},"publication_date":"2023-06-02","publication_name":{"en":"Mutation Research","ja":"Mutation Research"},"volume":"827","starting_page":"111826","ending_page":"111826","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.mrfmmm.2023.111826"],"issn":["1873-135X"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36775328","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85160204511","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471483","label":"url"}],"paper_title":{"en":"An Increase in Plasma MicroRNA-143 Levels in the Acute Phase Is Positively Correlated With Recovery of Cardiac Function in the Chronic Phase in Patients With Acute Myocardial Infarction","ja":"An Increase in Plasma MicroRNA-143 Levels in the Acute Phase Is Positively Correlated With Recovery of Cardiac Function in the Chronic Phase in Patients With Acute Myocardial Infarction"},"authors":{"en":[{"name":"Satake Atsushi"},{"name":"Minatoguchi Shingo"},{"name":"Heishima Kazuki"},{"name":"Yasuda Shinji"},{"name":"Murase Hirotaka"},{"name":"Yoshizumi Ryo"},{"name":"Komaki Hisaaki"},{"name":"Baba Shinya"},{"name":"Ojio Shinsuke"},{"name":"Tanaka Toshiki"},{"name":"Akao Yukihiro"},{"name":"Minatoguchi Shinya"},{"name":"Okura Hiroyuki"}],"ja":[{"name":"Satake Atsushi"},{"name":"Minatoguchi Shingo"},{"name":"平島 一輝"},{"name":"Yasuda Shinji"},{"name":"Murase Hirotaka"},{"name":"Yoshizumi Ryo"},{"name":"Komaki Hisaaki"},{"name":"Baba Shinya"},{"name":"Ojio Shinsuke"},{"name":"Tanaka Toshiki"},{"name":"Akao Yukihiro"},{"name":"Minatoguchi Shinya"},{"name":"Okura Hiroyuki"}]},"description":{"en":"MicroRNA (miR)-143 and miR-145 are non-coding RNAs present in smooth muscle cells and the heart. However, their behavior and physiological role in patients with acute myocardial infarction (AMI) have not been clarified. Plasma miR-143 and miR-145 concentrations were measured on Day 0 (on admission) and on Day 7 in AMI patients who could be followed up for 6 months (n=25). The control group consisted of subjects without significant coronary stenosis (n=20). Blood samples were collected from the antecubital vein, and plasma miR-143 and miR-145 concentrations were measured by quantitative reverse transcription-polymerase chain reaction. In AMI patients (n=25), left ventricular ejection fraction (LVEF) was measured by echocardiography in the acute and chronic (6 months) phases. On Day 7, plasma miR-143 and miR-145 concentrations were significantly higher in AMI patients than in the control group and on Day 0 in AMI patients. Plasma miR-143 and miR-145 concentrations increased significantly from Day 0 to Day 7. The increase in plasma miR-143 concentrations (∆miR-143) in the acute phase was positively correlated with the increase in LVEF in the chronic phase. Among many factors, only ∆miR-143 was favorably correlated with left ventricle (LV) functional recovery in the chronic phase. An increase in plasma miR-143 concentrations in the acute phase may be a biomarker predicting recovery of LV function in the chronic phase in AMI patients.","ja":"MicroRNA (miR)-143 and miR-145 are non-coding RNAs present in smooth muscle cells and the heart. However, their behavior and physiological role in patients with acute myocardial infarction (AMI) have not been clarified. Plasma miR-143 and miR-145 concentrations were measured on Day 0 (on admission) and on Day 7 in AMI patients who could be followed up for 6 months (n=25). The control group consisted of subjects without significant coronary stenosis (n=20). Blood samples were collected from the antecubital vein, and plasma miR-143 and miR-145 concentrations were measured by quantitative reverse transcription-polymerase chain reaction. In AMI patients (n=25), left ventricular ejection fraction (LVEF) was measured by echocardiography in the acute and chronic (6 months) phases. On Day 7, plasma miR-143 and miR-145 concentrations were significantly higher in AMI patients than in the control group and on Day 0 in AMI patients. Plasma miR-143 and miR-145 concentrations increased significantly from Day 0 to Day 7. The increase in plasma miR-143 concentrations (∆miR-143) in the acute phase was positively correlated with the increase in LVEF in the chronic phase. Among many factors, only ∆miR-143 was favorably correlated with left ventricle (LV) functional recovery in the chronic phase. An increase in plasma miR-143 concentrations in the acute phase may be a biomarker predicting recovery of LV function in the chronic phase in AMI patients."},"publication_date":"2023-02-11","publication_name":{"en":"Circulation Journal","ja":"Circulation Journal"},"volume":"87","number":"6","starting_page":"824","ending_page":"833","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1253/circj.CJ-22-0698"],"issn":["1347-4820"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471490","label":"url"}],"paper_title":{"en":"Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in a molecularly defined in vivo model","ja":"Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in a molecularly defined in vivo model"},"authors":{"en":[{"name":"Heishima Kazuki"},{"name":"Sugito, N."},{"name":"Abe, C."},{"name":"Hirata, A."},{"name":"Sakai, H."},{"name":"Akao, Y."}],"ja":[{"name":"平島 一輝"},{"name":"Sugito, N."},{"name":"Abe, C."},{"name":"Hirata, A."},{"name":"Sakai, H."},{"name":"Akao, Y."}]},"publication_date":"2023","publication_name":{"en":"Molecular Therapy. Nucleic Acids","ja":"Molecular Therapy. Nucleic Acids"},"volume":"33","starting_page":"960","ending_page":"982","languages":["eng"],"referee":true,"identifiers":{"issn":["2162-2531"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1016/J.OMTN.2022.09.001","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36189421","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85138586462","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471491","label":"url"}],"paper_title":{"en":"Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells","ja":"Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells"},"authors":{"en":[{"name":"Sugito, Nobuhiko"},{"name":"Heishima Kazuki"},{"name":"Akao, Yukihiro"}],"ja":[{"name":"Sugito, Nobuhiko"},{"name":"平島 一輝"},{"name":"Akao, Yukihiro"}]},"description":{"en":"Kirsten rat sarcoma virus (KRAS) mutations are frequently detected in many cancers and are major driver genes. Therefore, KRAS inhibitors have been the subject of extensive research. We developed chemically modified MIR143-3p (MIR143#12), which exhibits higher anticancer activity and nuclease resistance than other commercial inhibitors. MIR143#12 potently suppressed cell growth in colorectal and pancreatic cancer cell lines via apoptosis induced by repression of the entire rat sarcoma virus (RAS) network, which was achieved by silencing KRAS, Son of sevenless homolog 1 ( SOS1 ), AKT, and extracellular signal-regulated kinase (ERK). We investigated the mechanistic advantages of MIR143#12 in various KRAS mutant colorectal cancer cell lines. Its effects were stronger than those of knockdown of KRAS alone in colon cancer cells because silencing of KRAS by small interfering RNA (siRNA) did not decrease the protein expression levels of AKT or ERKs. The KRAS mRNA recruitment system, called the \"positive circuit\" under effector signaling pathways, may contribute to insensitivity of KRAS mutant cancers to MIR143#12 and siRNAs. In an in vivo study, we newly demonstrated that MIR143#12 induced neoangiogenesis in the tumor microenvironment with growth suppression. Based on the present results, it is crucial to down-regulate not only KRAS but also the entire KRAS signaling network, which may be accomplished by MIR143#12.","ja":"Kirsten rat sarcoma virus (KRAS) mutations are frequently detected in many cancers and are major driver genes. Therefore, KRAS inhibitors have been the subject of extensive research. We developed chemically modified MIR143-3p (MIR143#12), which exhibits higher anticancer activity and nuclease resistance than other commercial inhibitors. MIR143#12 potently suppressed cell growth in colorectal and pancreatic cancer cell lines via apoptosis induced by repression of the entire rat sarcoma virus (RAS) network, which was achieved by silencing KRAS, Son of sevenless homolog 1 ( SOS1 ), AKT, and extracellular signal-regulated kinase (ERK). We investigated the mechanistic advantages of MIR143#12 in various KRAS mutant colorectal cancer cell lines. Its effects were stronger than those of knockdown of KRAS alone in colon cancer cells because silencing of KRAS by small interfering RNA (siRNA) did not decrease the protein expression levels of AKT or ERKs. The KRAS mRNA recruitment system, called the \"positive circuit\" under effector signaling pathways, may contribute to insensitivity of KRAS mutant cancers to MIR143#12 and siRNAs. In an in vivo study, we newly demonstrated that MIR143#12 induced neoangiogenesis in the tumor microenvironment with growth suppression. Based on the present results, it is crucial to down-regulate not only KRAS but also the entire KRAS signaling network, which may be accomplished by MIR143#12."},"publication_date":"2022-12","publication_name":{"en":"Molecular Therapy. Nucleic Acids","ja":"Molecular Therapy. Nucleic Acids"},"volume":"30","starting_page":"49","ending_page":"61","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.omtn.2022.09.001"],"issn":["2162-2531"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1016/J.TETLET.2022.154092","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85137744348","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471496","label":"url"}],"paper_title":{"en":"Rapid total synthesis of petasin and isopetasin","ja":"Rapid total synthesis of petasin and isopetasin"},"authors":{"en":[{"name":"Okazaki, Keisuke"},{"name":"Takeda, Mitsumi"},{"name":"Yamaguch, Eiji"},{"name":"Heishima Kazuki"},{"name":"Itoh, Akichika"}],"ja":[{"name":"Okazaki, Keisuke"},{"name":"Takeda, Mitsumi"},{"name":"Yamaguch, Eiji"},{"name":"平島 一輝"},{"name":"Itoh, Akichika"}]},"publication_date":"2022-09","publication_name":{"en":"Tetrahedron Letters","ja":"Tetrahedron Letters"},"volume":"107","starting_page":"154092","ending_page":"154092","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.tetlet.2022.154092"],"issn":["0040-4039"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1016/J.JNUTBIO.2021.108922","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34856354","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85121601667","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471493","label":"url"}],"paper_title":{"en":"Plant hvu-MIR168-3p enhances expression of glucose transporter 1 (SLC2A1) in human cells by silencing genes related to mitochondrial electron transport chain complex I","ja":"Plant hvu-MIR168-3p enhances expression of glucose transporter 1 (SLC2A1) in human cells by silencing genes related to mitochondrial electron transport chain complex I"},"authors":{"en":[{"name":"Akao, Yukihiro"},{"name":"Kuranaga, Yuki"},{"name":"Heishima Kazuki"},{"name":"Sugito, Nobuhiko"},{"name":"Morikawa, Kohei"},{"name":"Ito, Yuko"},{"name":"Soga, Tomoyoshi"},{"name":"Ito, Tomohiro"}],"ja":[{"name":"Akao, Yukihiro"},{"name":"Kuranaga, Yuki"},{"name":"平島 一輝"},{"name":"Sugito, Nobuhiko"},{"name":"Morikawa, Kohei"},{"name":"Ito, Yuko"},{"name":"Soga, Tomoyoshi"},{"name":"Ito, Tomohiro"}]},"description":{"en":"Diet is a crucial factor for preventing most diseases. Edible plant extracts are known to contain exosome-like nanoparticles, in which food-derived plant microRNAs are included and may serve as a novel functional component in human health. Here, we demonstrated that hvu-MIR168-3p included in the nanoparticles of rice aleurone cells down-regulated the expression of the genes related to mitochondrial electron transport chain complex I in human cells. Subsequently, hvu-MIR168-3p enhanced protein and RNA expression levels of glucose transporter I and caused a decrease in the blood glucose level, which findings were obtained by in vitro and in vivo experiments, respectively. These findings suggest that a cross-kingdom relationship between plants and humans with respect to hvu-MIR168-3p exists and may contribute to preventive medicine for GLUT1-related dysfunctions including glucose metabolism, aging, and tumor immunology.","ja":"Diet is a crucial factor for preventing most diseases. Edible plant extracts are known to contain exosome-like nanoparticles, in which food-derived plant microRNAs are included and may serve as a novel functional component in human health. Here, we demonstrated that hvu-MIR168-3p included in the nanoparticles of rice aleurone cells down-regulated the expression of the genes related to mitochondrial electron transport chain complex I in human cells. Subsequently, hvu-MIR168-3p enhanced protein and RNA expression levels of glucose transporter I and caused a decrease in the blood glucose level, which findings were obtained by in vitro and in vivo experiments, respectively. These findings suggest that a cross-kingdom relationship between plants and humans with respect to hvu-MIR168-3p exists and may contribute to preventive medicine for GLUT1-related dysfunctions including glucose metabolism, aging, and tumor immunology."},"publication_date":"2022-03","publication_name":{"en":"The Journal of Nutritional Biochemistry","ja":"The Journal of Nutritional Biochemistry"},"volume":"101","starting_page":"108922","ending_page":"108922","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jnutbio.2021.108922"],"issn":["0955-2863"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://doi.org/10.1038/S41598-022-09655-2","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471497","label":"url"}],"paper_title":{"en":"Understanding of cell death induced by the constituents of Taxus yunnanensis wood","ja":"Understanding of cell death induced by the constituents of Taxus yunnanensis wood"},"authors":{"en":[{"name":"Heishima Kazuki"}],"ja":[{"name":"平島 一輝"}]},"publication_date":"2022","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"languages":["eng"],"referee":true,"identifiers":{"issn":["2045-2322"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1016/J.CHEMBIOL.2021.04.013","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33964212","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85116241949","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471503","label":"url"}],"paper_title":{"en":"Specific inhibition of oncogenic RAS using cell-permeable RAS-binding domains","ja":"Specific inhibition of oncogenic RAS using cell-permeable RAS-binding domains"},"authors":{"en":[{"name":"Nomura, Teiko Komori"},{"name":"Heishima Kazuki"},{"name":"Sugito, Nobuhiko"},{"name":"Sugawara, Ryota"},{"name":"Ueda, Hiroshi"},{"name":"Yukihiro, Akao"},{"name":"Honda, Ryo"}],"ja":[{"name":"Nomura, Teiko Komori"},{"name":"平島 一輝"},{"name":"Sugito, Nobuhiko"},{"name":"Sugawara, Ryota"},{"name":"Ueda, Hiroshi"},{"name":"Yukihiro, Akao"},{"name":"Honda, Ryo"}]},"description":{"en":"Oncogenic RAS proteins, common oncogenic drivers in many human cancers, have been refractory to conventional small-molecule and macromolecule inhibitors due to their intracellular localization and the lack of druggable pockets. Here, we present a feasible strategy for designing RAS inhibitors that involves intracellular delivery of RAS-binding domain (RBD), a nanomolar-affinity specific ligand of RAS. Screening of 51 different combinations of RBD and cell-permeable peptides has identified Pen-cRaf-v1 as a cell-permeable pan-RAS inhibitor capable of targeting both G12C and non-G12C RAS mutants. Pen-cRaf-v1 crosses the cell membrane via endocytosis, competitively inhibits RAS-effector interaction, and thereby exerts anticancer activity against several KRAS-mutant cancer cell lines. Moreover, Pen-cRaf-v1 exhibits excellent activity comparable with a leading pan-RAS inhibitor (BI-2852), as well as high target specificity in transcriptome analysis and alanine mutation analysis. These findings demonstrate that specific inhibition of oncogenic RAS, and possibly treatment of RAS-mutant cancer, is feasible by intracellular delivery of RBD.","ja":"Oncogenic RAS proteins, common oncogenic drivers in many human cancers, have been refractory to conventional small-molecule and macromolecule inhibitors due to their intracellular localization and the lack of druggable pockets. Here, we present a feasible strategy for designing RAS inhibitors that involves intracellular delivery of RAS-binding domain (RBD), a nanomolar-affinity specific ligand of RAS. Screening of 51 different combinations of RBD and cell-permeable peptides has identified Pen-cRaf-v1 as a cell-permeable pan-RAS inhibitor capable of targeting both G12C and non-G12C RAS mutants. Pen-cRaf-v1 crosses the cell membrane via endocytosis, competitively inhibits RAS-effector interaction, and thereby exerts anticancer activity against several KRAS-mutant cancer cell lines. Moreover, Pen-cRaf-v1 exhibits excellent activity comparable with a leading pan-RAS inhibitor (BI-2852), as well as high target specificity in transcriptome analysis and alanine mutation analysis. These findings demonstrate that specific inhibition of oncogenic RAS, and possibly treatment of RAS-mutant cancer, is feasible by intracellular delivery of RBD."},"publication_date":"2021-11","publication_name":{"en":"Cell Chemical Biology","ja":"Cell Chemical Biology"},"volume":"28","number":"11","starting_page":"1581","ending_page":"1589.e6","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.chembiol.2021.04.013"],"issn":["2451-9456"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://doi.org/10.1172/JCI139933","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471501","label":"url"}],"paper_title":{"en":"Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis","ja":"Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis"},"authors":{"en":[{"name":"Heishima Kazuki"}],"ja":[{"name":"平島 一輝"}]},"publication_date":"2021","publication_name":{"en":"The Journal of Clinical Investigation","ja":"The Journal of Clinical Investigation"},"languages":["eng"],"referee":true,"identifiers":{"issn":["0021-9738"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.3390/CANCERS12113312","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471505","label":"url"}],"paper_title":{"en":"Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by Interrupting RAS Pathways Including PAX3–FOXO1","ja":"Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by Interrupting RAS Pathways Including PAX3–FOXO1"},"authors":{"en":[{"name":"Sugito, Nobuhiko"},{"name":"Heishima Kazuki"},{"name":"Ito, Yuko"},{"name":"Akao, Yukihiro"}],"ja":[{"name":"Sugito, Nobuhiko"},{"name":"平島 一輝"},{"name":"Ito, Yuko"},{"name":"Akao, Yukihiro"}]},"publication_date":"2020-11","publication_name":{"en":"Cancers","ja":"Cancers"},"volume":"12","number":"11","starting_page":"3312","ending_page":"3312","languages":["eng"],"referee":true,"identifiers":{"issn":["2072-6694"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1007/S11060-020-03619-0","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471500","label":"url"}],"paper_title":{"en":"Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases","ja":"Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases"},"authors":{"en":[{"name":"Weiss, Sarah A."},{"name":"Zito, Christopher"},{"name":"Tran, Thuy"},{"name":"Heishima Kazuki"},{"name":"Neumeister, Veronique"},{"name":"McGuire, John"},{"name":"Adeniran, Adebowale"},{"name":"Kluger, Harriet"},{"name":"Jilaveanu, Lucia B."}],"ja":[{"name":"Weiss, Sarah A."},{"name":"Zito, Christopher"},{"name":"Tran, Thuy"},{"name":"平島 一輝"},{"name":"Neumeister, Veronique"},{"name":"McGuire, John"},{"name":"Adeniran, Adebowale"},{"name":"Kluger, Harriet"},{"name":"Jilaveanu, Lucia B."}]},"publication_date":"2020-09","publication_name":{"en":"Journal of Neuro-Oncology","ja":"Journal of Neuro-Oncology"},"volume":"152","number":"1","languages":["eng"],"referee":true,"identifiers":{"issn":["1573-7373"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.3390/JCM9082509","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471506","label":"url"}],"paper_title":{"en":"Tumor Tissue MIR92a and Plasma MIRs21 and 29a as Predictive Biomarkers Associated with Clinicopathological Features and Surgical Resection in a Prospective Study on Colorectal Cancer Patients","ja":"Tumor Tissue MIR92a and Plasma MIRs21 and 29a as Predictive Biomarkers Associated with Clinicopathological Features and Surgical Resection in a Prospective Study on Colorectal Cancer Patients"},"authors":{"en":[{"name":"Fukada, Masahiro"},{"name":"Matsuhashi, Nobuhisa"},{"name":"Takahashi, Takao"},{"name":"Sugito, Nobuhiko"},{"name":"Heishima Kazuki"},{"name":"Akao, Yukihiro"},{"name":"Yoshida, Kazuhiro"}],"ja":[{"name":"Fukada, Masahiro"},{"name":"Matsuhashi, Nobuhisa"},{"name":"Takahashi, Takao"},{"name":"Sugito, Nobuhiko"},{"name":"平島 一輝"},{"name":"Akao, Yukihiro"},{"name":"Yoshida, Kazuhiro"}]},"publication_date":"2020-08","publication_name":{"en":"Journal of Clinical Medicine","ja":"Journal of Clinical Medicine"},"volume":"9","number":"8","starting_page":"2509","ending_page":"2509","languages":["eng"],"referee":true,"identifiers":{"issn":["2077-0383"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1111/VCO.12580","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32072720","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85082587819","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471504","label":"url"}],"paper_title":{"en":"Development of synthetic microRNA 214 showing enhanced cytotoxicity and RNase resistance for treatment of canine hemangiosarcoma","ja":"Development of synthetic microRNA 214 showing enhanced cytotoxicity and RNase resistance for treatment of canine hemangiosarcoma"},"authors":{"en":[{"name":"Yoshikawa, Ryutaro"},{"name":"Heishima Kazuki"},{"name":"Ueno, Yoshihito"},{"name":"Kawade, Miwa"},{"name":"Maeda, Yusuke"},{"name":"Yoshida, Kyoko"},{"name":"Murakami, Mami"},{"name":"Sakai, Hiroki"},{"name":"Akao, Yukihiro"},{"name":"Mori, Takashi"}],"ja":[{"name":"Yoshikawa, Ryutaro"},{"name":"平島 一輝"},{"name":"Ueno, Yoshihito"},{"name":"Kawade, Miwa"},{"name":"Maeda, Yusuke"},{"name":"Yoshida, Kyoko"},{"name":"Murakami, Mami"},{"name":"Sakai, Hiroki"},{"name":"Akao, Yukihiro"},{"name":"Mori, Takashi"}]},"description":{"en":"MicroRNA-214 (miR-214), a pivotal tumour-suppressive miRNA, is downregulated in canine hemangiosarcoma (HSA) cells. Although these tumour-suppressive miRNAs are potential therapeutic agents, their clinical efficacy may be limited because of their vulnerability to RNase-rich microenvironments and low in vivo transfection rates. We developed synthetic miR-214s with enhanced cytotoxicity, RNase resistance and quantity of miR-214 in/on cells. These synthetic miR-214s were synthesized by various chemical modifications (such as 4'-aminoethyl-2'-fluoro, 2'-fluoro, 2'-O-methyl, phosphorothioate and oligospermine modifications) of the wild-type mature miR-214 sequences. Transfection of HSA cells with synthetic miR-214 (miR-214 5AE) demonstrated significant growth suppressive effect and induced the strongest apoptotic response. Synthetic miR-214s (miR-214 5AE, miR-214 10AE and miR-214 OS) were much more stable than mature miR-214s in foetal bovine serum. Similar to mature miR-214, 5AE and OS suppressed the expression level of COP1 in HSA cells. The quantity of synthetic miR-214s in/on cells was higher than that of mature miR-214. In conclusion, we developed a clinically applicable, synthetic miR-214 5AE that regulates the COP1 protein expression similar to that mediated by mature miR-214. Additionally, miR-214 5AE confers better cytotoxicity, nuclease resistance and transfection rate than mature miR-214. Thus, miR-214 5AE could potentially be a novel miRNA-based chemotherapeutic agent that could improve the prognosis of HSA. Its in vivo effects on canine HSA need to be examined in future.","ja":"MicroRNA-214 (miR-214), a pivotal tumour-suppressive miRNA, is downregulated in canine hemangiosarcoma (HSA) cells. Although these tumour-suppressive miRNAs are potential therapeutic agents, their clinical efficacy may be limited because of their vulnerability to RNase-rich microenvironments and low in vivo transfection rates. We developed synthetic miR-214s with enhanced cytotoxicity, RNase resistance and quantity of miR-214 in/on cells. These synthetic miR-214s were synthesized by various chemical modifications (such as 4'-aminoethyl-2'-fluoro, 2'-fluoro, 2'-O-methyl, phosphorothioate and oligospermine modifications) of the wild-type mature miR-214 sequences. Transfection of HSA cells with synthetic miR-214 (miR-214 5AE) demonstrated significant growth suppressive effect and induced the strongest apoptotic response. Synthetic miR-214s (miR-214 5AE, miR-214 10AE and miR-214 OS) were much more stable than mature miR-214s in foetal bovine serum. Similar to mature miR-214, 5AE and OS suppressed the expression level of COP1 in HSA cells. The quantity of synthetic miR-214s in/on cells was higher than that of mature miR-214. In conclusion, we developed a clinically applicable, synthetic miR-214 5AE that regulates the COP1 protein expression similar to that mediated by mature miR-214. Additionally, miR-214 5AE confers better cytotoxicity, nuclease resistance and transfection rate than mature miR-214. Thus, miR-214 5AE could potentially be a novel miRNA-based chemotherapeutic agent that could improve the prognosis of HSA. Its in vivo effects on canine HSA need to be examined in future."},"publication_date":"2020-04-01","publication_name":{"en":"Veterinary and Comparative Oncology","ja":"Veterinary and Comparative Oncology"},"volume":"18","number":"4","starting_page":"570","ending_page":"579","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/vco.12580"],"issn":["1476-5829"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.3390/IJMS20184406","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471509","label":"url"}],"paper_title":{"en":"Extracellular Vesicles Containing MicroRNA-92a-3p Facilitate Partial Endothelial-Mesenchymal Transition and Angiogenesis in Endothelial Cells","ja":"Extracellular Vesicles Containing MicroRNA-92a-3p Facilitate Partial Endothelial-Mesenchymal Transition and Angiogenesis in Endothelial Cells"},"authors":{"en":[{"name":"Yamada, Nami O."},{"name":"Heishima Kazuki"},{"name":"Akao, Yukihiro"},{"name":"Senda, Takao"}],"ja":[{"name":"Yamada, Nami O."},{"name":"平島 一輝"},{"name":"Akao, Yukihiro"},{"name":"Senda, Takao"}]},"publication_date":"2019-09","publication_name":{"en":"International Journal of Molecular Sciences","ja":"International Journal of Molecular Sciences"},"volume":"20","number":"18","starting_page":"4406","ending_page":"4406","languages":["eng"],"referee":true,"identifiers":{"issn":["1422-0067"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1186/S12917-019-1944-3","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471512","label":"url"}],"paper_title":{"en":"Plasma microRNA miR-26b as a potential diagnostic biomarker of degenerative myelopathy in Pembroke welsh corgis","ja":"Plasma microRNA miR-26b as a potential diagnostic biomarker of degenerative myelopathy in Pembroke welsh corgis"},"authors":{"en":[{"name":"Nakata, Kohei"},{"name":"Heishima Kazuki"},{"name":"Sakai, Hiroki"},{"name":"Yamato, Osamu"},{"name":"Furusawa, Yu"},{"name":"Nishida, Hidetaka"},{"name":"Maeda, Sadatoshi"},{"name":"Kamishina, Hiroaki"}],"ja":[{"name":"Nakata, Kohei"},{"name":"平島 一輝"},{"name":"Sakai, Hiroki"},{"name":"Yamato, Osamu"},{"name":"Furusawa, Yu"},{"name":"Nishida, Hidetaka"},{"name":"Maeda, Sadatoshi"},{"name":"Kamishina, Hiroaki"}]},"publication_date":"2019-06","publication_name":{"en":"BMC Veterinary Research","ja":"BMC Veterinary Research"},"volume":"15","number":"1","languages":["eng"],"referee":true,"identifiers":{"issn":["1746-6148"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1016/J.OMTM.2019.02.005","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471508","label":"url"}],"paper_title":{"en":"Anti-cancer Effects of a Chemically Modified miR-143 on Bladder Cancer by Either Systemic or Intravesical Treatment","ja":"Anti-cancer Effects of a Chemically Modified miR-143 on Bladder Cancer by Either Systemic or Intravesical Treatment"},"authors":{"en":[{"name":"Yoshikawa, Yuki"},{"name":"Taniguchi, Kohei"},{"name":"Tsujino, Takuya"},{"name":"Heishima Kazuki"},{"name":"Inamoto, Teruo"},{"name":"Takai, Tomoaki"},{"name":"Minami, Koichiro"},{"name":"Azuma, Haruhito"},{"name":"Miyata, Kanjiro"},{"name":"Hayashi, Kotaro"},{"name":"Kataoka, Kazunori"},{"name":"Akao, Yukihiro"}],"ja":[{"name":"Yoshikawa, Yuki"},{"name":"Taniguchi, Kohei"},{"name":"Tsujino, Takuya"},{"name":"平島 一輝"},{"name":"Inamoto, Teruo"},{"name":"Takai, Tomoaki"},{"name":"Minami, Koichiro"},{"name":"Azuma, Haruhito"},{"name":"Miyata, Kanjiro"},{"name":"Hayashi, Kotaro"},{"name":"Kataoka, Kazunori"},{"name":"Akao, Yukihiro"}]},"publication_date":"2019-06","publication_name":{"en":"Molecular Therapy. Methods & Clinical Development","ja":"Molecular Therapy. Methods & Clinical Development"},"volume":"13","languages":["eng"],"referee":true,"identifiers":{"issn":["2329-0501"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1016/J.YMTHE.2019.03.004","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471516","label":"url"}],"paper_title":{"en":"Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo","ja":"Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo"},"authors":{"en":[{"name":"Takai, Tomoaki"},{"name":"Tsujino, Takuya"},{"name":"Yoshikawa, Yuki"},{"name":"Inamoto, Teruo"},{"name":"Sugito, Nobuhiko"},{"name":"Kuranaga, Yuki"},{"name":"Heishima Kazuki"},{"name":"Soga, Tomoyoshi"},{"name":"Hayashi, Kotaro"},{"name":"Miyata, Kanjiro"},{"name":"Kataoka, Kazunori"},{"name":"Azuma, Haruhito"},{"name":"Akao, Yukihiro"}],"ja":[{"name":"Takai, Tomoaki"},{"name":"Tsujino, Takuya"},{"name":"Yoshikawa, Yuki"},{"name":"Inamoto, Teruo"},{"name":"Sugito, Nobuhiko"},{"name":"Kuranaga, Yuki"},{"name":"平島 一輝"},{"name":"Soga, Tomoyoshi"},{"name":"Hayashi, Kotaro"},{"name":"Miyata, Kanjiro"},{"name":"Kataoka, Kazunori"},{"name":"Azuma, Haruhito"},{"name":"Akao, Yukihiro"}]},"publication_date":"2019-05","publication_name":{"en":"Molecular Therapy","ja":"Molecular Therapy"},"volume":"27","number":"5","languages":["eng"],"referee":true,"identifiers":{"issn":["1525-0016"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1111/CAS.14035","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471510","label":"url"}],"paper_title":{"en":"MicroRNA‐143/Musashi‐2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer","ja":"MicroRNA‐143/Musashi‐2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer"},"authors":{"en":[{"name":"Tsujino, Takuya"},{"name":"Sugito, Nobuhiko"},{"name":"Taniguchi, Kohei"},{"name":"Honda, Ryo"},{"name":"Komura, Kazumasa"},{"name":"Yoshikawa, Yuki"},{"name":"Takai, Tomoaki"},{"name":"Minami, Koichiro"},{"name":"Kuranaga, Yuki"},{"name":"Shinohara, Haruka"},{"name":"Tokumaru, Yoshihisa"},{"name":"Heishima Kazuki"},{"name":"Inamoto, Teruo"},{"name":"Azuma, Haruhito"},{"name":"Akao, Yukihiro"}],"ja":[{"name":"Tsujino, Takuya"},{"name":"Sugito, Nobuhiko"},{"name":"Taniguchi, Kohei"},{"name":"Honda, Ryo"},{"name":"Komura, Kazumasa"},{"name":"Yoshikawa, Yuki"},{"name":"Takai, Tomoaki"},{"name":"Minami, Koichiro"},{"name":"Kuranaga, Yuki"},{"name":"Shinohara, Haruka"},{"name":"Tokumaru, Yoshihisa"},{"name":"平島 一輝"},{"name":"Inamoto, Teruo"},{"name":"Azuma, Haruhito"},{"name":"Akao, Yukihiro"}]},"publication_date":"2019-05","publication_name":{"en":"Cancer Science","ja":"Cancer Science"},"volume":"110","number":"7","languages":["eng"],"referee":true,"identifiers":{"issn":["1349-7006"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1186/S12917-019-1776-1","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471514","label":"url"}],"paper_title":{"en":"Prognostic significance of circulating microRNA-214 and -126 in dogs with appendicular osteosarcoma receiving amputation and chemotherapy","ja":"Prognostic significance of circulating microRNA-214 and -126 in dogs with appendicular osteosarcoma receiving amputation and chemotherapy"},"authors":{"en":[{"name":"Heishima Kazuki"},{"name":"Meuten, Travis"},{"name":"Yoshida, Kyoko"},{"name":"Mori, Takashi"},{"name":"Thamm, Douglas H."}],"ja":[{"name":"平島 一輝"},{"name":"Meuten, Travis"},{"name":"Yoshida, Kyoko"},{"name":"Mori, Takashi"},{"name":"Thamm, Douglas H."}]},"publication_date":"2019-01","publication_name":{"en":"BMC Veterinary Research","ja":"BMC Veterinary Research"},"volume":"15","number":"1","languages":["eng"],"referee":true,"identifiers":{"issn":["1746-6148"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1111/CAS.13913","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471513","label":"url"}],"paper_title":{"en":"Potent antiproliferative effect of fatty‐acid derivative AIC‐47 on leukemic mice harboring BCR‐ABL mutation","ja":"Potent antiproliferative effect of fatty‐acid derivative AIC‐47 on leukemic mice harboring BCR‐ABL mutation"},"authors":{"en":[{"name":"Shinohara, Haruka"},{"name":"Sugito, Nobuhiko"},{"name":"Kuranaga, Yuki"},{"name":"Heishima Kazuki"},{"name":"Minami, Yosuke"},{"name":"Naoe, Tomoki"},{"name":"Akao, Yukihiro"}],"ja":[{"name":"Shinohara, Haruka"},{"name":"Sugito, Nobuhiko"},{"name":"Kuranaga, Yuki"},{"name":"平島 一輝"},{"name":"Minami, Yosuke"},{"name":"Naoe, Tomoki"},{"name":"Akao, Yukihiro"}]},"publication_date":"2019-01","publication_name":{"en":"Cancer Science","ja":"Cancer Science"},"volume":"110","number":"2","languages":["eng"],"referee":true,"identifiers":{"issn":["1349-7006"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.5326/JAAHA-MS-6788","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471515","label":"url"}],"paper_title":{"en":"Short-Term Administration of Single-Agent Toceranib in Six Cases of Inoperable Massive Canine Hepatocellular Carcinoma","ja":"Short-Term Administration of Single-Agent Toceranib in Six Cases of Inoperable Massive Canine Hepatocellular Carcinoma"},"authors":{"en":[{"name":"Heishima Kazuki"},{"name":"Iwasaki, Ryota"},{"name":"Kawabe, Mifumi"},{"name":"Murakami, Mami"},{"name":"Sakai, Hiroki"},{"name":"Maruo, Kohji"},{"name":"Mori, Takashi"}],"ja":[{"name":"平島 一輝"},{"name":"Iwasaki, Ryota"},{"name":"Kawabe, Mifumi"},{"name":"Murakami, Mami"},{"name":"Sakai, Hiroki"},{"name":"Maruo, Kohji"},{"name":"Mori, Takashi"}]},"publication_date":"2019","publication_name":{"en":"Journal of the American Animal Hospital Association","ja":"Journal of the American Animal Hospital Association"},"volume":"55","number":"1","languages":["eng"],"referee":true,"identifiers":{"issn":["1547-3317"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1038/S41598-017-16795-3","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471523","label":"url"}],"paper_title":{"en":"Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity","ja":"Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity"},"authors":{"en":[{"name":"Su, Cathy"},{"name":"Gius, Jeffrey P."},{"name":"Van Steenberg, Julia"},{"name":"Haskins, Alexis H."},{"name":"Heishima Kazuki"},{"name":"Omata, Chisato"},{"name":"Iwayama, Masahiro"},{"name":"Murakami, Mami"},{"name":"Mori, Takashi"},{"name":"Maruo, Kohji"},{"name":"Kato, Takamitsu A."}],"ja":[{"name":"Su, Cathy"},{"name":"Gius, Jeffrey P."},{"name":"Van Steenberg, Julia"},{"name":"Haskins, Alexis H."},{"name":"平島 一輝"},{"name":"Omata, Chisato"},{"name":"Iwayama, Masahiro"},{"name":"Murakami, Mami"},{"name":"Mori, Takashi"},{"name":"Maruo, Kohji"},{"name":"Kato, Takamitsu A."}]},"publication_date":"2017-12","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"7","number":"1","languages":["eng"],"referee":true,"identifiers":{"issn":["2045-2322"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1111/VRU.12525","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28665494","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85021676740","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471524","label":"url"}],"paper_title":{"en":"Hypofractionated radiation therapy in the treatment of canine thymoma: Retrospective study of eight cases","ja":"Hypofractionated radiation therapy in the treatment of canine thymoma: Retrospective study of eight cases"},"authors":{"en":[{"name":"Goto, Sho"},{"name":"Murakami, Mami"},{"name":"Kawabe, Mifumi"},{"name":"Iwasaki, Ryota"},{"name":"Heishima Kazuki"},{"name":"Sakai, Hiroki"},{"name":"Mori, Takashi"}],"ja":[{"name":"Goto, Sho"},{"name":"Murakami, Mami"},{"name":"Kawabe, Mifumi"},{"name":"Iwasaki, Ryota"},{"name":"平島 一輝"},{"name":"Sakai, Hiroki"},{"name":"Mori, Takashi"}]},"description":{"en":"Thymomas are one of the most common tumors of the cranial mediastinum in dogs; however there is limited information available on the use of radiation therapy for treating this neoplasm. Objectives of the current retrospective observational study were to describe outcomes and side effects of a hypofractionated radiation therapy protocol in a group of dogs with confirmed thymoma. A total of eight dogs were included. To generate individualized treatment plans, we designed the planning target volume according to the limits on mean lung dose and the percentage of the total lung volume exceeding 20 Gy (V20). The total administered dose was 48-49 Gy, with one fraction per week for a total of six to seven fractions. After therapy, two dogs achieved complete responses, two achieved partial responses, and the disease remained stable in two. Two dogs died during the radiation therapy protocol and were not classified. The median mean lung dose and V20 were 6.0 Gy (range: 3.1-15.0 Gy) and 12.4% (range: 2.3-27.5%), respectively. The overall response rate was 50.0%, and the median time to response following treatment initiation was 22 days (range: 14-115 days). Acute and late side effects were common in the skin and/or lung and were self-limiting or asymptomatic. The median survival time was not reached (range: 8-1128 days) and the 1 year survival rate was 75.0%. Hypofractionated radiation therapy was well tolerated in this sample of dogs with thymoma and may be considered when owners decline surgical treatment or the tumor is deemed unresectable.","ja":"Thymomas are one of the most common tumors of the cranial mediastinum in dogs; however there is limited information available on the use of radiation therapy for treating this neoplasm. Objectives of the current retrospective observational study were to describe outcomes and side effects of a hypofractionated radiation therapy protocol in a group of dogs with confirmed thymoma. A total of eight dogs were included. To generate individualized treatment plans, we designed the planning target volume according to the limits on mean lung dose and the percentage of the total lung volume exceeding 20 Gy (V20). The total administered dose was 48-49 Gy, with one fraction per week for a total of six to seven fractions. After therapy, two dogs achieved complete responses, two achieved partial responses, and the disease remained stable in two. Two dogs died during the radiation therapy protocol and were not classified. The median mean lung dose and V20 were 6.0 Gy (range: 3.1-15.0 Gy) and 12.4% (range: 2.3-27.5%), respectively. The overall response rate was 50.0%, and the median time to response following treatment initiation was 22 days (range: 14-115 days). Acute and late side effects were common in the skin and/or lung and were self-limiting or asymptomatic. The median survival time was not reached (range: 8-1128 days) and the 1 year survival rate was 75.0%. Hypofractionated radiation therapy was well tolerated in this sample of dogs with thymoma and may be considered when owners decline surgical treatment or the tumor is deemed unresectable."},"publication_date":"2017-06-30","publication_name":{"en":"Veterinary Radiology & Ultrasound","ja":"Veterinary Radiology & Ultrasound"},"volume":"58","number":"5","starting_page":"613","ending_page":"620","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/vru.12525"],"issn":["1740-8261"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1111/VCO.12323","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28524617","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85042354332","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471520","label":"url"}],"paper_title":{"en":"Metastatic diagnosis of canine sternal lymph nodes using computed tomography characteristics: A retrospective cross-sectional study.","ja":"Metastatic diagnosis of canine sternal lymph nodes using computed tomography characteristics: A retrospective cross-sectional study."},"authors":{"en":[{"name":"Iwasaki R"},{"name":"Murakami M"},{"name":"Kawabe M"},{"name":"Heishima Kazuki"},{"name":"Sakai H"},{"name":"Mori T"}],"ja":[{"name":"Iwasaki R"},{"name":"Murakami M"},{"name":"Kawabe M"},{"name":"平島 一輝"},{"name":"Sakai H"},{"name":"Mori T"}]},"description":{"en":"The accurate evaluation of sternal lymph nodes (StLNs) is critical for the staging of canine thoraco-abdominal tumours. Computed tomography (CT) provides a non-invasive means of assessing StLNs, but its diagnostic accuracy for identifying metastases is unclear. In this retrospective cross-sectional study, we assessed the diagnostic power of various CT measurements. Fifty-seven dogs that underwent concurrent CT and cytological examination of the StLNs were enrolled retrospectively. The size, shape, X-ray attenuation and uniformity of the StLNs were assessed. The dogs were divided into metastasis-negative (n = 21) and metastasis-positive (n = 36) groups. Logistic regression analysis showed that the size (StLN-to-second sternebra ratio [ratio-size]) and precontrast attenuation were significantly different between groups. Combining these parameters achieved a specificity and positive predictive value of 100% (cut-off values: 1.0, 37.5 Hounsfield units, respectively). This suggests that the combination of ratio-size and precontrast attenuation is effective for differentiating metastasis to the StLNs on CT.","ja":"The accurate evaluation of sternal lymph nodes (StLNs) is critical for the staging of canine thoraco-abdominal tumours. Computed tomography (CT) provides a non-invasive means of assessing StLNs, but its diagnostic accuracy for identifying metastases is unclear. In this retrospective cross-sectional study, we assessed the diagnostic power of various CT measurements. Fifty-seven dogs that underwent concurrent CT and cytological examination of the StLNs were enrolled retrospectively. The size, shape, X-ray attenuation and uniformity of the StLNs were assessed. The dogs were divided into metastasis-negative (n = 21) and metastasis-positive (n = 36) groups. Logistic regression analysis showed that the size (StLN-to-second sternebra ratio [ratio-size]) and precontrast attenuation were significantly different between groups. Combining these parameters achieved a specificity and positive predictive value of 100% (cut-off values: 1.0, 37.5 Hounsfield units, respectively). This suggests that the combination of ratio-size and precontrast attenuation is effective for differentiating metastasis to the StLNs on CT."},"publication_date":"2017-05-19","publication_name":{"en":"Veterinary and Comparative Oncology","ja":"Veterinary and Comparative Oncology"},"volume":"16","number":"1","starting_page":"140","ending_page":"147","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/vco.12323"],"issn":["1476-5829"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1038/S41598-017-02607-1","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471522","label":"url"}],"paper_title":{"en":"Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease","ja":"Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease"},"authors":{"en":[{"name":"Heishima Kazuki"},{"name":"Ichikawa, Yukie"},{"name":"Yoshida, Kyoko"},{"name":"Iwasaki, Ryota"},{"name":"Sakai, Hiroki"},{"name":"Nakagawa, Takayuki"},{"name":"Tanaka, Yuiko"},{"name":"Hoshino, Yuki"},{"name":"Okamura, Yasuhiko"},{"name":"Murakami, Mami"},{"name":"Maruo, Kohji"},{"name":"Akao, Yukihiro"},{"name":"Mori, Takashi"}],"ja":[{"name":"平島 一輝"},{"name":"Ichikawa, Yukie"},{"name":"Yoshida, Kyoko"},{"name":"Iwasaki, Ryota"},{"name":"Sakai, Hiroki"},{"name":"Nakagawa, Takayuki"},{"name":"Tanaka, Yuiko"},{"name":"Hoshino, Yuki"},{"name":"Okamura, Yasuhiko"},{"name":"Murakami, Mami"},{"name":"Maruo, Kohji"},{"name":"Akao, Yukihiro"},{"name":"Mori, Takashi"}]},"publication_date":"2017-05","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"7","number":"1","languages":["eng"],"referee":true,"identifiers":{"issn":["2045-2322"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.5326/JAAHA-MS-6339","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471525","label":"url"}],"paper_title":{"en":"Mandibular Reconstruction by Using a Liquid Nitrogen-Treated Autograft in a Dog with an Oral Tumor","ja":"Mandibular Reconstruction by Using a Liquid Nitrogen-Treated Autograft in a Dog with an Oral Tumor"},"authors":{"en":[{"name":"Okamura, Yasuhiko"},{"name":"Heishima Kazuki"},{"name":"Motegi, Tomoki"},{"name":"Sasaki, Jun"},{"name":"Goryo, Masanobu"},{"name":"Nishida, Hideji"},{"name":"Tsuchiya, Hiroyuki"},{"name":"Katayama, Masaaki"},{"name":"Uzuka, Yuji"}],"ja":[{"name":"Okamura, Yasuhiko"},{"name":"平島 一輝"},{"name":"Motegi, Tomoki"},{"name":"Sasaki, Jun"},{"name":"Goryo, Masanobu"},{"name":"Nishida, Hideji"},{"name":"Tsuchiya, Hiroyuki"},{"name":"Katayama, Masaaki"},{"name":"Uzuka, Yuji"}]},"publication_date":"2017","publication_name":{"en":"Journal of the American Animal Hospital Association","ja":"Journal of the American Animal Hospital Association"},"volume":"53","number":"3","languages":["eng"],"referee":true,"identifiers":{"issn":["1547-3317"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.3390/IJMS161025377","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471527","label":"url"}],"paper_title":{"en":"MicroRNA-214 and MicroRNA-126 Are Potential Biomarkers for Malignant Endothelial Proliferative Diseases","ja":"MicroRNA-214 and MicroRNA-126 Are Potential Biomarkers for Malignant Endothelial Proliferative Diseases"},"authors":{"en":[{"name":"Heishima Kazuki"},{"name":"Mori, Takashi"},{"name":"Ichikawa, Yukie"},{"name":"Sakai, Hiroki"},{"name":"Kuranaga, Yuki"},{"name":"Nakagawa, Takayuki"},{"name":"Tanaka, Yuiko"},{"name":"Okamura, Yasuhiko"},{"name":"Masuzawa, Mikio"},{"name":"Sugito, Nobuhiko"},{"name":"Murakami, Mami"},{"name":"Yamada, Nami"},{"name":"Akao, Yukihiro"},{"name":"Maruo, Kohji"}],"ja":[{"name":"平島 一輝"},{"name":"Mori, Takashi"},{"name":"Ichikawa, Yukie"},{"name":"Sakai, Hiroki"},{"name":"Kuranaga, Yuki"},{"name":"Nakagawa, Takayuki"},{"name":"Tanaka, Yuiko"},{"name":"Okamura, Yasuhiko"},{"name":"Masuzawa, Mikio"},{"name":"Sugito, Nobuhiko"},{"name":"Murakami, Mami"},{"name":"Yamada, Nami"},{"name":"Akao, Yukihiro"},{"name":"Maruo, Kohji"}]},"publication_date":"2015-10","publication_name":{"en":"International Journal of Molecular Sciences","ja":"International Journal of Molecular Sciences"},"volume":"16","number":"10","languages":["eng"],"referee":true,"identifiers":{"issn":["1422-0067"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.1371/JOURNAL.PONE.0137361","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471526","label":"url"}],"paper_title":{"en":"MicroRNA-214 Promotes Apoptosis in Canine Hemangiosarcoma by Targeting the COP1-p53 Axis","ja":"MicroRNA-214 Promotes Apoptosis in Canine Hemangiosarcoma by Targeting the COP1-p53 Axis"},"authors":{"en":[{"name":"Heishima Kazuki"},{"name":"Mori, Takashi"},{"name":"Sakai, Hiroki"},{"name":"Sugito, Nobuhiko"},{"name":"Murakami, Mami"},{"name":"Yamada, Nami"},{"name":"Akao, Yukihiro"},{"name":"Maruo, Kohji"}],"ja":[{"name":"平島 一輝"},{"name":"Mori, Takashi"},{"name":"Sakai, Hiroki"},{"name":"Sugito, Nobuhiko"},{"name":"Murakami, Mami"},{"name":"Yamada, Nami"},{"name":"Akao, Yukihiro"},{"name":"Maruo, Kohji"}]},"publication_date":"2015-09","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"10","number":"9","starting_page":"e0137361","ending_page":"e0137361","languages":["eng"],"referee":true,"identifiers":{"issn":["1932-6203"]},"published_paper_type":"scientific_journal"}}
{"insert":{"user_id":"B000291909","type":"published_papers"},"force":{"see_also":[{"@id":"http://dx.doi.org/10.14814/PHY2.12135","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=471529","label":"url"}],"paper_title":{"en":"Estimation of glomerular filtration rate in conscious mice using a simplified equation","ja":"Estimation of glomerular filtration rate in conscious mice using a simplified equation"},"authors":{"en":[{"name":"Sasaki, Yui"},{"name":"Iwama, Ryosuke"},{"name":"Sato, Tsubasa"},{"name":"Heishima Kazuki"},{"name":"Shimamura, Shunsuke"},{"name":"Ichijo, Tosihiro"},{"name":"Satoh, Hiroshi"},{"name":"Furuhama, Kazuhisa"}],"ja":[{"name":"Sasaki, Yui"},{"name":"Iwama, Ryosuke"},{"name":"Sato, Tsubasa"},{"name":"平島 一輝"},{"name":"Shimamura, Shunsuke"},{"name":"Ichijo, Tosihiro"},{"name":"Satoh, Hiroshi"},{"name":"Furuhama, Kazuhisa"}]},"publication_date":"2014-08","publication_name":{"en":"Physiological Reports","ja":"Physiological Reports"},"volume":"2","number":"8","starting_page":"e12135","ending_page":"e12135","languages":["eng"],"referee":true,"identifiers":{"issn":["2051-817X"]},"published_paper_type":"scientific_journal"}}